Celltex Therapeutics successfully used to bank stem cells for juvenile idiopathic arthritis treatment

A young patient has successfully used Celltex Therapeutics to culture and bank his own stem cells to be for use in treating his severe case of systemic juvenile idiopathic arthritis.

Advertisement

Celltex Therapeutics is a biotechnology company established to initiate breakthroughs in regenerative medicine, specifically in the autologous stem cell field.

 

Six-year-old Tucker Beau Hyatt has suffered from juvenile arthritis since he was two. Following the stem cell therapy, vast improvements in Tucker Beau’s appetite and his body were noted. He is now able to run and play without pain.

More articles on devices:

5 quick notes on Precision Spine’s MD-Max ULIF System: Dr. Donald Kucharzyk
LDR’s 4Q revenue up 23.6%: 12 key notes
Orthocell’s expands Asia presence; tendon repair therapy used in Hong Kong

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.